";s:4:"text";s:4047:" Articles of Dolutegravir Sodium are included as well. [Na+].C[C@@H]1CCO[C@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N12
The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens. CAS registry number (Chemical Abstracts Service) 1051375-16-6. SODIUM (4R,12AS)-9-(((2,4-DIFLUOROPHENYL)METHYL)CARBAMOYL)-4-METHYL-6,8-DIOXO-3,4,6,8,12,12A-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-B)(1,3)OXAZIN-7-OLATE2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-B)(1,3)OXAZINE-9-CARBOXAMIDE, N-((2,4-DIFLUOROPHENYL)METHYL)-3,4,6,8,12,12A-HEXAHYDRO-7-HYDROXY-4-METHYL-6,8-DIOXO-, SODIUM SALT (1:1), (4R,12AS)- Stability. Dolutegravir . The recommended dose is 50 mg once daily or twice daily depending on therapy. Select one or more newsletters to continue.
N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
This means it is still under development and may contain inaccuracies. Dolutegravir Impurity 9 .
Inhibits HIV integrase that catalyzes strand transfer × $ £ € ... Molecular Weight: 419.38: References. C20-H19-F2-N3-O5.
Dolutegravir exhibited antiviral activity against 13 clinically diverse clade B isolates with a mean EC50 value of 0.52 nM in a viral integrase susceptibility assay using the integrase coding region from clinical isolates. National Center for Advancing Translational Sciences (NCATS),
Available for Android and iOS devices. Properties were generated using the CDK toolkit. 39 Dolutegravir also readily crosses the placenta; therefore, mothers receiving this treatment will be exposing neonates to dolutegravir, with or without breastfeeding.
It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional.
(2013)
Dolutegravir EC50 values against 3 HIV-2 clinical isolates in PBMC assays ranged from 0.09 nM to 0.61 nM.
It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. For all sales inquiries please contact: sales@biosynth-carbosynth.com OR Call your local office.
US Approved Rx
The dolutegravir transfer into breast milk in a mother–infant pair was previously estimated to be equal to a daily infant exposure of 0.015 mg/kg.
Rec.INN. Molecular Weight: 418.3708: Charge-1: Count: Stereochemistry: ABSOLUTE: Additional Stereochemistry: Defined Stereocenters: 2 / 2: E/Z Centers: 0: Optical Activity : UNSPECIFIED Description.
US Approved Rx
Specification: View: MSDS: View: CONTACT INFORMATION. Background: An unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. (2013)
All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand.